1-5 of 5
Klaus Hoeffken, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Survival after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation in AML-Patients Is Consistently Sustained and Influenced by Donor Type Selection.

Herbert G. Sayer, MD, Lars-Olof Muegge, MD, Sebastian Scholl, MD, Kristina Schilling, MD, Anne Klink, Volker Schmidt, Klaus Hoeffken, MD
Journal: Blood
Blood (2007) 110 (11): 5087.
https://doi.org/10.1182/blood.V110.11.5087.5087
Published: 2007
Journal Articles

Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma - 42 Months Follow Up Results of the OSHO 39 Study.

Michael Herold, MD, Antje Haas, MD, Stephanie Srock, MD, Sabine Neser, MD, Kathrin H. Al Ali, MD, Andreas Neubauer, MD, Gottfried Doelken, MD, Ralph Naumann, MD, Thomas Fietz, MD, Mathias Freund, MD, Robert Rohrberg, MD, Klaus Hoeffken, MD, Martin Mohren, MD, Thomas H. Ittel, MD, Erika Kettner, MD
Journal: Blood
Blood (2007) 110 (11): 4474.
https://doi.org/10.1182/blood.V110.11.4474.4474
Published: 2007
Journal Articles

Addition of Rituximab to First-Line MCP (Mitoxantrone, Chlorambucil, Prednisolone) Chemotherapy Prolongs Survival in Advanced Follicular Lymphoma - 4 Year Follow-Up Results of a Phase III Trial of the East German Study Group Hematology and Oncology (OSHO#39).

Michael Herold, MD, Antje Haas, MD, Stephanie Srock, MD, Sabine Neser, MD, Kathrin H. Al Ali, MD, Andreas Neubauer, MD, Gottfried Doelken, MD, Ralph Naumann, MD, Thomas Fietz, MD, Mathias Freund, MD, Robert Rohrberg, MD, Klaus Hoeffken, MD, Astrid Franke, MD, Thomas H. Ittel, MD, Erika Kettner, MD
Journal: Blood
Blood (2006) 108 (11): 484.
https://doi.org/10.1182/blood.V108.11.484.484
Published: 2006
Journal Articles

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

Michael Herold, MD, Rita Pasold, MD, Stefanie Srock, MD, Sabine Neser, MD, Dietger Niederwieser, MD, Andreas Neubauer, MD, Gottfried Dölken, MD, Ralph Naumann, MD, Thomas Fietz, MD, Mathias Freund, MD, Robert Rohrberg, MD, Klaus Hoeffken, MD, Astrid Franke, MD, Thomas H. Ittel, MD, Erika Kettner, MD, Ursula Haak, MD, Ullrich Mey, MD, Christian Klinkenstein, MD, Michael Assmann, MD, Ullrich von Gruenhagen, MD, Klaus Dachselt, MD, Helga Schwenke, MD, Dorothee Bleyl, MD, Heiner Wolf, MD, Sabine Hahnfeld, MD, Franz-Adolph Hoffmann, MD, Volker Lakner, MD, Peter Richter, MD, Detlev Hähling, MD, H. H. Wolf, MD, Henning Eschenburg, MD, M.-R. Clemens, MD, Norbert Grobe, MD
Journal: Blood
Blood (2004) 104 (11): 584.
https://doi.org/10.1182/blood.V104.11.584.584
Published: 2004
Journal Articles

Cost Evaluation of Rituximab Plus MCP vs. MCP Alone in Advanced Stage Indolent Non-Hodgkin’s-Lymphoma Based on a Randomized Controlled Multicenter Trial.

Klaus Hieke, Rita Pasold, MD, Sabine Neser, MD, Dietger Niederwieser, MD, Andreas Neubauer, MD, Gottfried Doelken, MD, Ralph Naumann, MD, Thomas Fietz, MD, Mathias Freund, MD, Robert Rohrberg, MD, Klaus Hoeffken, MD, Astrid Franke, MD, Thomas-Hein Ittel, MD, Erika Kettner, MD, Ursula Haak, MD, Ullrich Mey, MD, Christian Klinkenstein, MD, M. Assmann, MD, Ullrich von Gruenhagen, MD, Klaus Dachselt, MD, Helga Schwenke, MD, Dorothee Bleyl, MD, Heiner Wolf, MD, Sabine Hahnfels, MD, Franz-Adolph Hoffmann, MD, Volker Lakner, MD, Peter Richter, MD, Detlev Haehling, MD, H.H. Wolf, MD, H. Eschenburg, MD, N. Grobe, MD, M.-R. Clemens, MD, Michael Herold, MD
Journal: Blood
Blood (2004) 104 (11): 87.
https://doi.org/10.1182/blood.V104.11.87.87
Published: 2004